PAHC PHIBRO ANIMAL HEALTH CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 1069899 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.1%
TTM net income YoY51.5%
TTM EPS YoY49.7%
Revenue 3-yr CAGR16.4%
Net income 3-yr CAGR70.5%
Margins
Gross margin33.8%
Operating margin12.5%
Net margin6.7%
FCF margin1.4%
EBITDA margin15.9%
Returns
ROE28.2%
ROA7.1%
ROIC (approx.)15.6%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets72.4%
Debt / equity1.46x
Current ratio3.20x
Interest coverage4.18x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio1.2%
Payout ratio19.0%
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.52B | $1.30B | $1.02B | $977.89M | $942.26M |
| Cost of revenue | $1.01B | $896.27M | $704.59M | $679.65M | $656.86M |
| Gross profit | $512.51M | $399.94M | $313.09M | $298.24M | $285.40M |
| R&D expense | $24.55M | $23.73M | $29.19M | $24.39M | $20.83M |
| SG&A expense | $318.12M | $289.48M | $259.78M | $226.39M | $206.41M |
| Operating income | $194.40M | $110.47M | $53.31M | $71.85M | $78.99M |
| Interest expense | $46.42M | $37.22M | $23.01M | $18.68M | $12.69M |
| Pretax income | $137.35M | $67.99M | $10.92M | $54.07M | $72.33M |
| Income tax | $37.63M | $19.73M | $8.50M | $21.46M | $23.15M |
| Net income | $99.72M | $48.26M | $2.42M | $32.61M | $49.17M |
| EBITDA | $245.91M | $156.07M | $89.49M | $105.86M | $111.69M |
| EPS (basic) | 2.46 | 1.19 | 0.06 | 0.81 | 1.21 |
| EPS (diluted) | 2.43 | 1.19 | 0.06 | 0.81 | 1.21 |
| Dividends declared per share | 0.48 | 0.48 | 0.48 | 0.48 | 0.48 |
| Weighted avg. shares (diluted) | 40.96M | 40.68M | 40.52M | 40.50M | 40.50M |
| Banking | |||||
| Net interest income | — | — | — | -$15.32M | -$11.88M |
| Balance sheet | |||||
| Cash & equivalents | $61.42M | $68.04M | $70.61M | $41.28M | $74.25M |
| Short-term investments | $20.57M | $9.00M | $44.00M | $40.00M | $17.00M |
| Receivables | $238.79M | $227.98M | $169.45M | $163.48M | $166.54M |
| Inventory | $534.88M | $444.43M | $265.91M | $277.57M | $259.16M |
| Current assets | $935.51M | $810.61M | $601.00M | $585.72M | $566.23M |
| PP&E, net | $369.17M | $354.69M | $203.30M | $195.57M | $165.49M |
| Goodwill | $60.05M | $59.65M | $54.56M | $53.27M | $53.23M |
| Intangibles | $30.05M | $36.47M | $45.03M | $54.99M | $63.86M |
| Total assets | $1.50B | $1.36B | $982.18M | $971.40M | $931.70M |
| Current liabilities | $316.47M | $293.47M | $204.15M | $176.00M | $190.83M |
| Short-term debt | $25.02M | $16.25M | $29.80M | $22.30M | $15.00M |
| Long-term debt | $591.77M | $615.43M | $282.29M | $311.54M | $272.93M |
| Total debt | $616.79M | $631.68M | $312.08M | $333.84M | $287.93M |
| Total liabilities | $1.12B | $1.08B | $725.54M | $688.89M | $669.26M |
| Shareholders' equity | $385.48M | $285.68M | $256.64M | $282.51M | $262.44M |
| Net debt | $555.38M | $563.65M | $241.47M | $292.56M | $213.68M |
| Cash flow statement | |||||
| Operating cash flow | $68.95M | $80.12M | $87.59M | $13.31M | $31.65M |
| Capital expenditure | $59.09M | $38.29M | $41.24M | $51.79M | $37.04M |
| Free cash flow | $9.87M | $41.83M | $46.36M | -$38.48M | -$5.39M |
| Investing cash flow | -$71.45M | -$288.69M | -$48.19M | -$74.02M | -$22.58M |
| Financing cash flow | -$6.56M | $207.13M | -$6.77M | $26.99M | $16.34M |
| Depreciation & amortization | $51.51M | $45.60M | $36.18M | $34.01M | $32.70M |
| Stock-based compensation | $1.60M | $717,000 | $475,000 | — | — |
| Dividends paid | $19.46M | $19.45M | $19.44M | $19.44M | $19.44M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.